The Quickly Evolving Treatment Landscape of Metastatic Urothelial Carcinoma: A New Standard of Care in First-Line Systemic Therapy
bladder cancer, metastatic urothelial carcinoma, EV-302 trial, KEYNOTE-A39 study, enfortumab vedotin, pembrolizumab, enfortumab vedotin plus pembrolizumab, CheckMate 901 study, nivolumab plus gemcitabine/cisplatin, nivolumab, gemcitabine, antibody-drug conjugate targeting Nectin-4, NCT04223856, methotrexate, vinblastine, doxorubicin, MVAC, Avelumab, JAVELIN bladder 100, APOBEC mutation signatures, KEYNOTE-B15 study, EV-304 trial, NCT04700124.